Institution statistics

K.A.B.S. LABORATORIES INC. - KABS - Canada

Ranking results:

Past rankings:

Ranking timeline:

European project participation (2010-01-01 - 2021-12-31 ):

Performance:

Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:

Leadership:

Total number of projects: 2
As coordinator: 0
As participant: 2
Sole participant: 0
Coordinator / Participant Ratio: 0^*

^*Ratio includes only projects with > 2 partners

Summary:

	Total project funding [€]:			Projects [No]:
Year:	coordinator^*	participant^*	per partner	as coordinator	as participant
2020	0	3.662.963	438.376		1
2013	0	2.190.998	0		1

^*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:

Institution:	Projects [No]:
ACADEMIC MEDICAL CENTRE AMSTERDAM	1
BIOIMAGES RESEARCH LIMITED	1
COBRA BIOLOGICS LIMITED	1
ERGOMED CLINICAL RESEARCH LIMITED	1
EXVASTAT	1
GALENICA AB	1
HOSPICES CIVILS DE LYON	1
MEDIZINISCHES VERSORGUNGSZENTRUM INSTITUT FUR MIKROOKOLOGIE	1
NEDERLANDSE ORGANISATIE VOOR TOEGEPAST NATUURWETENSCHAPPELIJK ONDERZOEK TNO	1
ORION SANTE SARL	1
OXTHERA AB	1
STICHTING VUMC	1
SYMBIO PHARM	1
UNIVERSITAETSKLINIKUM BONN	1
UNIVERSITY COLLEGE LONDON HOSPITALSNHS FOUNDATION TRUST	1

Constancy:

Total number of partners:15

Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 15

Frequent / Rare Partner Ratio: 0

Diversity:

Subjects:

Subject:	No:
REGIONAL DEVELOPMENT	1

Diversity index:1

Categories:

Category:	No:
SOCIAL AND ECONOMIC CONCERNS	1

Project overview:

Start date	Project	acronym	role	funding	partners
2020-07-01	Development of Impentri, an intravenous imatinib formulation for Covid-19 acute respiratory distress syndrome (ARDS).	Impentri	participant	3.662.963	5
2013-10-01	Biopharmaceutical therapy for treatment of Primary Hyperoxaluria	ELIMOX	participant	2.190.998	12

Data provision: © European Union; Source: CORDIS, http://cordis.europa.eu/ | This page is not provided by the European Commission see:Impressum